Author + information
- Nicolas Cecere, MD,
- Michel Jadoul, MD and
- Laura Labriola, MD∗ ()
- ↵∗Nephrology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Avenue Hippocrate 10, Brussels B1200, Belgium
In a recent randomized, controlled, multicenter trial, Han et al. (1) showed that rosuvastatin, compared with “standard of care,” significantly reduced the risk of contrast-induced acute kidney injury (AKI) in diabetic patients with chronic kidney disease undergoing an intra-arterial contrast medium injection. On the basis of Figure 3, the authors claim that rosuvastatin was consistently effective among various subgroups. We disagree. No effect (p = 0.89) was observed in approximately 43% of patients given intravenous hydration (the standard of care, not given consistently in this study, in contrast to the authors’ claim). Thus, we conclude that rosuvastatin may at best prevent contrast-induced AKI in some patients not given intravenous hydration. The latter will remain the cornerstone of the prevention of contrast-induced AKI, as summarized by the Class I Level of Evidence: A in the recent Kidney Disease: Improving Global Outcomes guidelines (KDIGO) (2).